Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine in Malaria-exposed Adults in Burkina Faso
NCT07730177Phase 1Not yet recruiting
- Sponsor
- Sanaria Inc.
- Start
- Mar 2027
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ-LARC2 in malaria (3 arms), sponsored by Sanaria Inc. Primary endpoints: Efficacy of PfSPZ-LARC2 Vaccine against infection with Plasmodium falciparum malaria, Safety and tolerability - grade 3 solicited AEs and 3 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07730177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730177.